Halozyme Therapeutics Inc (NASDAQ: HALO) has seen a decline in its stock price by -0.38 in relation to its previous close of 57.92. However, the company has experienced a 0.45% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-02-26 that SAN DIEGO, Feb. 26, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the TD Cowen 45th Annual Healthcare Conference. The presentation is scheduled for Wednesday, March 5 at 8:50am PT / 11:50am ET.
Is It Worth Investing in Halozyme Therapeutics Inc (NASDAQ: HALO) Right Now?
Halozyme Therapeutics Inc (NASDAQ: HALO) has a price-to-earnings ratio of 16.81x that is above its average ratio. Additionally, the 36-month beta value for HALO is 1.33. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for HALO is 121.75M and currently, short sellers hold a 7.57% ratio of that float. The average trading volume of HALO on February 28, 2025 was 1.29M shares.
HALO’s Market Performance
The stock of Halozyme Therapeutics Inc (HALO) has seen a 0.45% increase in the past week, with a 3.04% rise in the past month, and a 17.76% gain in the past quarter. The volatility ratio for the week is 2.55%, and the volatility levels for the past 30 days are at 2.52% for HALO. The simple moving average for the last 20 days is 0.22% for HALO stock, with a simple moving average of 8.02% for the last 200 days.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with Wells Fargo repeating the rating for HALO by listing it as a “Equal Weight.” The predicted price for HALO in the upcoming period, according to Wells Fargo is $62 based on the research report published on October 07, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see HALO reach a price target of $57, previously predicting the price at $52. The rating they have provided for HALO stocks is “Neutral” according to the report published on September 19th, 2024.
Piper Sandler gave a rating of “Neutral” to HALO, setting the target price at $51 in the report published on June 07th of the previous year.
HALO Trading at 7.22% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.95% of loss for the given period.
Volatility was left at 2.52%, however, over the last 30 days, the volatility rate increased by 2.55%, as shares surge +3.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.64% upper at present.
During the last 5 trading sessions, HALO rose by +0.45%, which changed the moving average for the period of 200-days by +31.61% in comparison to the 20-day moving average, which settled at $57.57. In addition, Halozyme Therapeutics Inc saw 20.69% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HALO starting from LaBarre Michael J., who sale 10,000 shares at the price of $58.12 back on Feb 26 ’25. After this action, LaBarre Michael J. now owns 175,453 shares of Halozyme Therapeutics Inc, valued at $581,244 using the latest closing price.
LaBarre Michael J., the SVP, CHIEF TECHNICAL OFFICER of Halozyme Therapeutics Inc, sale 10,000 shares at $58.05 during a trade that took place back on Feb 25 ’25, which means that LaBarre Michael J. is holding 185,453 shares at $580,534 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- 0.54 for the present operating margin
- 0.81 for the gross margin
The net margin for Halozyme Therapeutics Inc stands at 0.44. The total capital return value is set at 0.29. Equity return is now at value 198.42, with 22.79 for asset returns.
Based on Halozyme Therapeutics Inc (HALO), the company’s capital structure generated 0.81 points at debt to capital in total, while cash flow to debt ratio is standing at 0.32. The debt to equity ratio resting at 4.14. The interest coverage ratio of the stock is 30.48.
Currently, EBITDA for the company is 656.54 million with net debt to EBITDA at 2.15. When we switch over and look at the enterprise to sales, we see a ratio of 8.37. The receivables turnover for the company is 3.29for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.80.
Conclusion
In conclusion, Halozyme Therapeutics Inc (HALO) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
